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Abstract 
EBV infection is ubiquitous in humans, but the majority of infections have an asymptomatic or self-
limiting clinical course.  Rarely, individuals may develop a pathological EBV infection with a variety of 
life threatening complications (including haemophagocytosis and malignancy) and others develop 
asymptomatic chronic EBV viraemia.  Although an impaired ability to control EBV infection has long 
been recognised as a hallmark of severe T-cell immunodeficiency, the advent of next generation 
sequencing has identified a series of Primary Immunodeficiencies in which EBV-related pathology is 
the dominant feature.  Chronic active EBV infection is defined as chronic EBV viraemia associated 
with systemic lymphoproliferative disease, in the absence of immunodeficiency. Descriptions of 
larger cohorts of patients with chronic active EBV in recent years have significantly advanced our 
understanding of this clinical syndrome.  In this review we summarise the current understanding of 
the pathophysiology and natural history of these diseases and clinical syndromes, and discuss 
approaches to the investigation and treatment of severe or atypical EBV infection. 
  
Introduction 
Epstein Barr Virus is a γ-herpesvirus characterised by restricted infectious specificity to humans, and 
latent infection in B lymphocytes.  EBV is naturally transmitted through saliva (Gerber et al. 1972).  
Primary infection with EBV typically occurs in childhood as a symptomless or mild infection, with 
early infection seen in a higher proportion of the population of low income compared to high 
income countries (Cohen 2000; Pariente et al. 2007; Hjalgrim, Friborg, and Melbye 2007)(e.g. 58.9% 
of Zambian infants aged 12 months are EBV seropositive (Minhas et al. 2010) compared to 7.1% of 
infants in a Swedish infants (Hesla et al. 2013)).  By age 30, >95% of adults in Europe and North 
America are seropositive (Cohen 2000; Pariente et al. 2007; Pembrey et al. 2013).  Primary EBV 
infection in adolescence or adulthood leads to a 25-70% risk of developing a symptomatic EBV 
infection, known as infectious mononucleosis (IM) (Higgins et al. 2007; McAulay et al. 2007).  This is 
characterised by pharyngitis, benign lymphoproliferation, fever and malaise, and symptoms lasts up 
to 6 weeks duration in the majority of patients. 
Following primary infection, EBV persists within resting memory B cells (Miyashita et al. 1997) with 
low immunogenicity (Babcock, Hochberg, and Thorley-Lawson 2000), allowing a life-long infection to 
be established, which the immune system cannot clear. 
EBV Life cycle 
EBV has a biphasic life cycle, divided into lytic and latent gene expression programmes (Tsurumi, 
Fujita, and Kudoh 2005)(figure 1).  The lytic gene expression programmes allow EBV to productively 
infect new cells and new hosts, while establishment of latency is vital to allow life-long persistence 
of the virus within infected cells, through a highly restricted gene expression profile in order to avoid 
immune surveillance (Young, Arrand, and Murray 2007). 
The first cells thought to be infected by EBV during primary infection are oral epithelial cells and 
naïve B cells (Balfour et al. 2013).  During the lytic cycle, EBV infection is followed by the induction of 
two immediate early proteins (BRLF1 and BZLF1) which act as transcriptional activators for a wide 
range of proteins and viral RNAs involved in viral DNA replication or viral structural proteins.  True 
latency (type 0), where cells express no EBV protein or RNA, but retain senescent episomal EBV DNA, 
is subsequently established in the resting B memory pool.  Although this transition to latency is not 
fully understood, a model proposing EBV exploitation of the physiological B-cell differentiation 
pathway is helpful when considering the pathological states following EBV infection (Thorley-Lawson 
et al. 2013)).  In this, infected naïve B cells enter a proliferative phase during which they express the 
full range of latent EBV proteins and viral RNAs (latency type 3, equivalent of in vitro derived B 
lymphoblastoid cell lines).  A proportion of these cells differentiate further into latency type 2 within 
the oropharyngeal germinal centres in response to EBV-specific T follicular helper cells, resulting in 
restriction of EBV protein expression to EBV nuclear antigen (EBNA) 1, latent membrane protein 
(LMP) 1 and 2 proteins only.  Further differentiation results in the release of latency type 0 resting B 
memory cells into the circulation.  Sporadically, as these cells recirculate through the oropharynx, a 
proportion switch from the immunologically silent latent infection, to the productive lytic cycle.   
The virus is shed at particularly high levels from four-six weeks after initial infection (Dunmire et al. 
2015), reducing as the infected individual convalesces.  Low-level shedding of EBV in saliva (and the 
possibility of infecting new hosts) continues sporadically for life (Hadinoto et al. 2009), as cycles of 
lytic reactivation within B-cells and oropharyngeal epithelial cells are interrupted by immunological 
control, leading to a return to latent infection (Taylor et al. 2015).   
From epidemiological studies and in vitro work, a number of factors have been identified which may 
drive the change from a latent to a lytic gene expression profile in cells infected with EBV (Kenney 
2007). In latently infected individuals it has been shown that stress (e.g. caused by sleep deprivation) 
leads to increased EBV genome production (Uchakin et al. 2011; Mehta et al. 2000) and EBV lytic 
transcription factor BZLF1 may be induced by glucocorticoids (Yang et al. 2010) demonstrating a link 
between the host environment and permissivity of viral reactivation.  Suppression of T-cell immunity 
(for example after organ transplantation) is also strongly associated with EBV reactivation (Hiwarkar 
et al. 2013), as is concurrent infection with some other pathogens, such as Group A Streptococcus 
(Ueda et al. 2014) and malaria (Plasmodium falciparum) (Moormann et al. 2005; Rochford, Cannon, 
and Moormann 2005; Rickinson 2014). 
Immune Response to EBV infection 
Primary EBV infection in the immunocompetent host leads to distinct antibody profiles.  The EBV 
proteins expressed during lytic infection, such as Viral Capsid Antigen (VCA) and Immediate Early 
Antigen (EA), are often highly immunogenic with antibodies to VCA detectable up to a week before 
the onset of IM symptoms.  Antibodies responses to latent proteins are delayed, with EBNA2 specific 
IgG appearing at the height of symptoms, and the anti-EBNA1 IgG response developing from 3 
months post-infection.  The hallmark of primary EBV infection is detectable IgM and rising IgG VCA 
antibody responses, in the absence of an EBNA1 IgG response (Taylor et al. 2015).  In a study of 
individuals who had recently experienced IM, 88% of individuals were positive for VCA-IgM, 100% 
were positive for VCA-IgG, and 96% were positive for EBNA1-IgG (Balfour et al. 2013).   
Studies of individuals in the early stages of EBV seroconversion show an expansion in peripheral 
Natural Killer (NK) cells at the point of symptom onset, 4-6 weeks after initial infection (Balfour et al. 
2013).  Although NK-cell numbers correlate with virus load in the peripheral blood, they 
demonstrate little evidence of increased activation, as measured by levels of granzyme B.  CD8+ T-
cell expansion follows the same pattern with a dramatic proliferation of lytic antigen specific CD8+ T-
cells during IM, and a much smaller response to latent antigens.  Onset of symptoms correlates 
much more closely with this CD8+ cell expansion, than with EBV viral load, supporting a model of IM 
as an immunopathic disease (Balfour et al. 2013).  During asymtpomatic EBV infection, there is 
similar development of EBV-specific CD8+ve cells, with clonal dominance of the CD8+ repertoire, 
however the total CD8+ T-cell counts remain within the normal range, suggesting activated CD8+ T-
cell over-proliferation is associated with symptomatic disease(Jayasooriya et al. 2015).  CD4+ T-cell 
expansion also occurs during IM, although this is less dramatic than the CD8+ response.  By contrast 
to CD8+ cells, the CD4+ response is predominantly towards latent EBV antigens and demonstrates 
less clonal immunodominance, with a wider distribution of epitope responses.  A detailed review the 
immune response to EBV infection can be found elsewhere (Taylor et al. 2015).   
Pathological Responses to EBV infection 
Although the majority of individuals infected with EBV have an asymptomatic or self-limiting clinical 
course, there is a broad range of pathological responses to infection, encompassing prolonged fever 
and lymphoproliferation (severe IM), haemophagocytic lymphohistiocytsosis, autoimmunity and 
malignancy.  These states arise from unregulated cytotoxic and inflammatory responses to EBV 
infected B-cells, impaired T-cell or NK-cell immune surveillance of EBV infected cells, EBV infection in 
aberrant (non-B) cells or as yet undefined mechanisms.  Each of these pathological mechanisms can 
be in seen in immunodeficient patients (primary and secondary) or apparently normal hosts.  Our 
understanding of the interaction between EBV and the host response to infection is improving, but 
we are far from truly appreciating the complexities of genetically determined susceptibility to 
pathological EBV-associated states. 
Haemophagocytic lymphohistiocytosis (HLH) 
HLH is a severe, life-threatening immunodysregulatory disorder resulting from the uncontrolled 
activation and proliferation of T-cells and macrophages, which causes excessive production of 
cytokines, hyperinflammation and tissue damage.  It is classified as either primary HLH, when a 
family history of the disorder or identified genetic defect is present, or secondary HLH which can be 
associated with infection, rheumatological disorders (often termed macrophage activation 
syndrome) or malignancy.  It is debatable whether all patients with ‘secondary HLH’ also have a 
genetic susceptibility to develop a hyperinflammatory response to a trigger, and indeed evidence in 
support of this theory is emerging (Zhang et al. 2008; Weaver and Behrens 2014; Zhang et al. 2014).  
Increasingly, HLH is also recognised as complication of more “classical” primary 
immunuodeficiencies (PIDs) (Bode et al. 2015).  The causes of primary HLH and the investigations 
required for their diagnosis are summarised in Table 1. 
In the normal setting, cytotoxic T lymphocytes (CTLs) and NK-cells, once in contact with a virally 
infected cell, respond by forming an immunological synapse with the target cell followed by granule-
mediated cytotoxicity.  This not only clears the virally infected cells but regulates the inflammatory 
response by removing antigenic stimulus.  All forms of familial HLH result from impaired granule-
dependent cytotoxicity due to abnormalities in the trafficking, docking and exocytosis of granules, or 
in perforin function. Perforin is a key protein in this process, creating pores in the target cell 
membrane to allow entry of granzymes leading to target cell death (Voskoboinik, Smyth, and Trapani 
2006).  Without target cell death, antigen presenting cells continue to stimulate CTLs, leading to the 
ongoing production of cytokines, in particular IFN-γ, which further drives macrophage activation and 
histiocytic transformation (Jordan et al. 2004).  Macrophages and activated T cells infiltrate tissues 
secreting high levels of inflammatory cytokines, chemokines and other substances that lead to the 
symptoms of HLH.  Cytopenias result from both haemophagocytosis and high levels of TNF-α, IFN-γ 
and ferritin which suppresses haematopoiesis (Larroche and Mouthon 2004).  Much of our 
understanding HLH comes from the immunopathology of familial cytotoxicity defect syndromes, 
however the pathogenesis of other forms of primary and secondary HLH is likely to involve the same 
mechanisms.   
Regardless of the underlying cause, the clinical features of HLH are similar, although patients with 
primary HLH tend to present in infancy (Janka 2007; Cetica et al. 2016).  Clinical manifestations 
include prolonged fever, hepatosplenomegaly, hepatitis, cytopenias, coagulopathy, rashes and 
neurological symptoms.  The Histiocyte Society has developed diagnostic criteria for HLH, based on 
both clinical and laboratory findings (Table 2), to help guide the initiation of therapy.   
Standard of care treatment remains established, highly immunosuppressive, chemotherapeutic 
protocols (HLH 94 and HLH 2004 (Henter et al. 2007; Henter et al. 2002)) combining etoposide (VP-
16) with steroid therapy, +/- ciclosporin, with the aim of removing and controlling destructive 
immune cells and suppressing inflammation.  If neurological features are present intrathecal 
methotrexate should be included.  Supportive care is vitally important as is treating suspected 
triggers, including EBV infection, which may require multiple courses of Rituximab.  Published data 
suggests that 71% of patient achieve remission on the HLH 94 protocol but 29% of patients die 
before reaching transplant and 5-year survival post-HSCT is 54% (Trottestam et al. 2011).  Following 
induction therapy patients with primary HLH should proceed urgently to Haematopoietic Stem Cell 
transplant (HSCT).  Long term management of secondary/undefined HLH is more difficult; however 
our practice is to progress to HSCT in patients with refractory or relapsing HLH even in the absence 
of a defined genetic aetiology.   
It is critical to achieve remission prior to HSCT as the outcome in patients with active HLH is 
significantly worse.  The introduction of reduced intensity conditioning (RIC) regimes has improved 
the outlook for patients with primary HLH affording 3-year survival rates of 92% compared to 43% 
when myeloablative conditioning is used (Marsh, Vaughn, et al. 2010).  Results still remain disease 
specific, with certain inherited disorders associated with reduced survival post-HSCT as highlighted 
below.  Detailed reviews of treatment strategies including salvage therapy and the increasing use of 
anti-thymocyte globulin (ATG) and monoclonal antibodies in this context are available (Jordan et al. 
2011; Mahlaoui et al. 2007). 
Chronic Active EBV (CAEBV) 
Chronic Active EBV (CAEBV) was originally used to describe patients with chronic or recurrent 
infectious mononucleosis (Straus 1988).  It is now defined as EBV related illness lasting greater than 
3 months, associated with systemic EBV positive lymphoproliferative disease (LPD) (with elevated 
EBV DNA/RNA in affected tissues), and high level EBV viraemia or increased anti-VCA IgG titre, in the 
absence of defined primary or secondary immunodeficiency (Cohen et al. 2011; Kimura et al. 2005; 
Kimura et al. 2001; Kimura et al. 2012; Okano et al. 2005) (see table 2).  CAEBV has been most 
commonly described in East Asia where the proliferating cells are usually T or NK-cells (Kimura et al. 
2012).  This clinically heterozygous condition has overlap with two cutaneous syndromes – Hydroa 
Vacciniforme-like lymphoma (a recurrent vesiculopapular eruption usually caused by an EBV infected 
γδT-cell infiltration) and mosquito bite sensitivity associated with EBV positive lymphoproliferation 
(usually NK-cells) (Kimura, Kawada, and Ito 2013) (see figure 2).  In Western countries, CAEBV is rarer 
but usually associated with B cell proliferation (Cohen et al. 2011).  In all of these conditions the 
lymphocyte, and EBV clonality may be monoclonal, oligoclonal or polyclonal. 
Clinically CAEBV patients demonstrate an aggressive course with complications ranging from 
progression to HLH and/or lymphoma, disseminated intravascular coagulopathy, coronary artery 
aneurysms, CNS disease, myocarditis, pneumonitis and gastrointestinal perforation (Kimura et al. 
2001; Kimura et al. 2012; Cohen et al. 2011).  In the largest series of 108 patients with EBV-
associated T/NK-cell LPD, survival at a median follow up of 46 months was 44%.  Patients with 
isolated cutaneous disease appear to have a better prognosis and those with CD4+ T cells as the EBV 
infected proliferative cell, do worse (Kimura et al. 2012).  Complications and prognosis for CAEBV 
with B-cell lymphoproliferation in the US seems to be similar, although interestingly 42% of these 
patients developed progressive hypogammaglobulinaemia and B-cell lymphopenia (even in the 
absences of rituximab therapy) (Cohen et al. 2011) 
CAEBV patients have significantly higher loads of EBV DNA in mononuclear cells compared to 
patients with IM (Xing et al. 2013).  Characteristically, patients have very high IgG antibody titres to 
EBV early antigen (EA) and VCA, but lack an IgG response to EBNA1 (Kimura et al. 2003), however, 
this pattern may be absent in up to 50% of patients and is therefore of limited diagnostic value.  The 
pathophysiology of CAEBV is poorly understood.  Despite the above antibody pattern being 
suggestive of a predominance of EBV lytic cycle infection, T and NK-cells demonstrate EBV infection 
in type 2 latency (Kimura et al. 2005).  CAEBV patients have a hyperinflammatory state with cytokine 
profiles (raised IL-1β, IL10, IFNγ) similar to patients with familial HLH (Ohga et al. 2001), suggesting 
an equivalent pathophysiology, with impaired removal of EBV infected T/NK-cells driving a local 
inflammatory response in infiltrated tissues, and a resultant pro-oncogenic and haemophagocytic 
environment (Rickinson 2014). 
EBV-positive systemic T-cell lymphoproliferative disease (STLPD) is a lymphoma of αβ T-cells with an 
activated phenotype.  It usually develops following acute EBV infection, but can also arise as a 
malignant progression from CAEBV (Kimura, Kawada, and Ito 2013).  By definition this is a systemic 
illness caused by clonal proliferation of EBV infected T cells (Quintanilla-Martinez, Kimura, and Jaffe 
2008).  It almost invariably is associated with haemophagocytosis, and as the proliferating cells 
rarely show evidence of atypica the differentiation from HLH or CAEBV is often difficult.  It is perhaps 
best thought of as the common neoplastic path of lymphoid proliferation in both HLH and CAEBV 
(Hong et al. 2013).  Interestingly the presence of monoclonality in HLH does not appear to impact on 
outcome (Ahn et al. 2010). 
Treatment of CAEBV and STLPD remains unsatisfactory, with most patients treated according to their 
predominant clinical syndrome (HLH or lymphoma).  Rituximab, antiviral and chemotherapeutic 
drugs and may have a role in stabilising early disease in occasional patients, but any clinical benefit 
doesn’t appear to be sustained.  Results of early HSCT with RIC are encouraging, suggesting that 
conservative therapy should be reserved for patients with isolated cutaneous disease and easily 
controlled inflammation (Kimura et al. 2012; Cohen et al. 2011; Kawa et al. 2011). 
EBV driven malignancy and autoimmunity 
EBV-driven malignancy is seen in both immunocompentent and immunodeficient patients, with 
malignant transformation of lymphoid cells (T, B and NK-cells), and non-haematopoeitic cells (Figure 
2).  Pathophysiology is multifactorial with the following being key pathogenic processes; (1) loss of 
immune surveillance / EBV-mediate immune evasion, (2) EBV infection induced growth factor and 
cytokine production, (3) EBV oncogene expression (particularly LMP1 and LMP2A) and (4) genetic / 
epigenetic alteration of the host genome.  The relative importance of each of these mechanisms 
varies for each individual malignancy (Murata, Sato, and Kimura 2014; Rickinson 2014; Taylor et al. 
2015).   
EBV has also been implicated in the pathophysiology of autoimmunity, best characterised by 
associations with multiple sclerosis and systemic lupus erythematosis (Taylor et al. 2015; Thacker, 
Mirzaei, and Ascherio 2006) 
Common human genetic variation in EBV infection and immunity 
Susceptibility to EBV infection and disease may be described as a spectrum.  At one end lie rare 
monogenic mutations with large effects (Houldcroft and Kellam 2015), and at the other end are 
common polymorphisms with small effects, leading to subtle changes in risk of, and response to, 
infection.  In the middle is a less well defined category of low-frequency variants which are 
associated with disease phenotypes, but are also found in apparently healthy members of the 
population (Manso et al. 2014), with no clear biological impact on gene function. 
Genome-wide association studies (GWAS) are beginning to impact on our understanding of the 
common genetic variants underlying population response to EBV infection.  Individuals vary in their 
antibody titres to EBNAs, and the heritability and common genetic variants underlying this variability 
have been probed in a number of recent studies.  A series of GWAS have identified single nucleotide 
polymorphisms (SNPs) within HLA class II genes as important for antibody response to EBV, 
specifically IgG antibodies to EBNA-1 (Hammer et al. 2015; Pedergnana et al. 2014; Rubicz et al. 
2013). 
Candidate gene studies have also associated anti-VCA IgA and IgG titres to variants in a number of 
genes (Houldcroft and Kellam, 2015), but these variants have yet to be validated by the more 
agnostic GWAS approach.  Many candidate gene studies have focused on functional variants within 
the promoter region of interleukin-10 (IL10) (reviewed in (Houldcroft and Kellam 2015), in part 
because EBV encodes a viral homolog of IL10 (BCRF1) (Moore et al. 1990), but also because of the 
many roles IL10 plays in EBV infection, (regulatory T cell response to EBV (Marshall, Vickers, and 
Barker 2003), promotion of latent infected B cell survival (Incrocci, McCormack, and Swanson-
Mungerson 2013)).   
(Houldcroft and Kellam 2015)Candidate gene studies have also suggested variants within the HLA 
class 1 system as being important for susceptibility to EBV infection (Durovic et al. 2013), and risk of 
symptomatic infection (IM versus silent seroconversion) (McAulay et al. 2007).  Finding the common 
genetic variants underpinning infectious mononucleosis is an achievable goal for approaches such as 
GWAS, as studies of IM risk in twins (Hwang et al. 2012) demonstrate that monozygotic twins have 
twice the relative risk of concordance for symptomatic IM compared to dizygotic twins.  Similarly, 
first degree relatives (Rostgaard, Wohlfahrt, and Hjalgrim 2014) show a heritable component of IM 
risk, based on studies of individuals hospitalised with severe IM, with rate ratios of IM increasing as 
genetic relatedness increased.   
EBV genome variation and its role in disease 
In addition to genetic susceptibility of the host, it is possible that genetic variability in the EBV 
genome may play a role in the pathogenesis of severe EBV infection. 
The genome of EBV is approximately 184kb long, formed of linear double-stranded DNA.  Following 
primary infection, EBV persists in B cells as an episome and does not normally integrate into the 
human genome, although aberrant EBV integration events are seen in some EBV-positive cancers 
Raab-Traub 2007).  Genetically and phenotypically, there are two types of EBV (1 and 2) and these 
types have different geographic distributions.  EBV type 1 is most prevalent and occurs worldwide, 
while EBV type 2 seropositivity shows widespread geographic variation and is reported in 20-25% of 
EBV seropositive individuals in parts of Africa and Melanesia (Young et al. 1987).  Co-infection with 
EBV type 1 and EBV type 2 is infrequently detected (Chang et al. 2009).  Recombinant strains 
between EBV type 1 and EBV type 2 have been also reported (Burrows et al. 1996). 
EBV type 2 transforms B cells more poorly than EBV type 1, and there is some in vivo evidence that 
type 2 EBV transforms T cells more successfully than B cells (Coleman et al. 2015).  Host genes are 
differentially expressed following infection with type 1 compared to type 2 EBV strains, with IL1β, 
ADAMDEC1 and MARCKS all significantly up-regulated following infection with type 1 compared to 
type 2 EBV (Lucchesi et al. 2008).  There are other patterns of diversity across individual EBV genes, 
but they do not lead to such clear patterns of genome differentiation as the type 1/type 2 distinction 
(Palser et al. 2015). 
To date, there are no whole-genome sequences of EBV isolated from patients with CAEBV.  The 
number of EBV genome sequences from healthy individuals is also very small, which adds to the 
challenge of distinguishing disease-associated viral variants from normal variation.  Studies of EBV 
variation in HLH (Kelesidis et al. 2012) have focused on small regions of candidate genes (eg LMP1 
showing within and between group diversity in EBV sequenced from different populations (Tzellos 
and Farrell 2012)), but have been unable to distinguish variation that may contribute to disease from 
normal variation.  Studies which aim to identify disease-associated viral variants would benefit from 
a case-control approach similar to that used in genome-wide association studies, comparing the EBV 
genome sequences of CAEBV patients with age and location-matched controls. 
Primary Immune Deficiencies associated with severe EBV disease 
Herpesvirus infections are particularly problematic for patients with monogenic defects of the 
immune system, and severe or persistent EBV infection is a hallmark combined or innate primary 
immunodeficiency.  Among these diverse disorders there is a subset of conditions which appear to 
have a particular susceptibility to developing pathogenic consequences of EBV infection, and these 
are summarised below.  Interestingly these disorders share a number of functional immune defects 
including cytotoxicity, T-cell receptor signalling, effective antibody production, cell migration and 
regulation of apoptosis (table 3).  Investigation of patients presenting with severe or atypical EBV 
infection should focus on early identification of a possible PID or characterisation of an HLH or 
CAEBV clinical state.  A proposed investigation algorithm is shown in figure figure 3. 
Additionally several patients with combined immunodeficiency have chronic asymptomatic EBV 
viraemia.  Optimal management of these patients is unknown, however careful long term 
monitoring is essential. 
X-linked Lymphoproliferative Disease (XLP) / SAP deficiency 
XLP-1 is a rare primary immunodeficiency first described over forty years ago (Purtilo et al. 1975) 
and the clinical features, which include HLH, lymphoma and dysgammaglobulinaemia, remain 
constant in more recently described cohorts (Seemayer et al. 1995; Sumegi et al. 2000; Booth et al. 
2011).  Overall mortality has reduced over time but HLH still remains fatal in the majority of patients 
with this manifestation (Booth et al. 2011).  XLP results from mutations in the SH2D1A gene which 
encodes the SLAM-associated protein (SAP).  SAP is an intracellular adaptor molecule expressed in T, 
NK and NKT cells and is a key regulator of normal immune function.  Immune defects described in 
XLP patients include reduced or absent NKT cells (Nunez-Cruz et al. 2008), abnormal NK and CD8+ T-
cell cytotoxicity (Parolini et al. 2000; Tangye et al. 2000; Dupre et al. 2005) and compromised 
reactivation induced cell death, all of which could explain the abnormal response to viral infection 
(Snow et al. 2009).  Defective CD4+ T follicular helper cell function leads to impaired antibody 
function, and lack of memory B cells and long lived plasma cells (Veillette et al. 2008; Crotty et al. 
2003; Qi et al. 2008). 
Although XLP is associated with an increased susceptibility to severe EBV disease, the finding that up 
to 35% of patients are EBV negative at diagnosis supports our understanding of XLP as a disorder of 
severe immune dysregulation, with HLH, lymphoma and humoral abnormalities described in EBV 
negative patients (Booth et al. 2011).  No significant difference in mortality was seen between EBV 
positive and EBV negative patients. 
Management relies on appropriate treatment of HLH and lymphoproliferation, with most patients 
requiring immunoglobulin replacement therapy.  Rituximab is routinely used to reduce EBV viral 
load.  Survival following HSCT is 81% but mortality increases to 50% in patients with HLH.  Survival 
for un-transplanted patients is reported as 63% but again outcome is extremely poor in the context 
of HLH with survival plummeting to 19% (Booth et al. 2011).  A murine model of XLP has been 
corrected using HSC gene therapy and this approach may offer, in the future, an alternative 
treatment strategy for patients lacking a suitable donor for HSCT (Rivat et al. 2013).   
XIAP deficiency 
X-linked inhibitor of apoptosis (XIAP) deficiency is caused by mutations in the BIRC4 gene and 
although initially described as XLP-2 due to similarities in clinical presentation to boys with SAP 
deficiency (Rigaud et al. 2006), it is now recognised as a more complex disorder of immune 
dysregulation with a wide spectrum of clinical manifestations.  XIAP is ubiquitously expressed and 
appears to have several roles in immune cells including in NOD-1 and NOD-2 signalling pathways, 
involved in detection of bacterial infection, alongside its anti-apoptotic role (Aguilar and Latour 
2015).  Patients with XIAP deficiency have reduced NKT-cell numbers and lymphocytes demonstrate 
increased activation induced cell death (AICD).  NK-cell cytotoxicity is normal (Marsh, Madden, et al. 
2010).  Diagnosis can be made through flow cytometric analysis of protein expression and genetic 
analysis.  A functional assay demonstrating impaired TNFα production in response to NOD2 pathway 
stimulation in monocytes has also been described (Ammann et al. 2014). 
A number of case series have now been published which confirm the main clinical features as HLH 
(which is often recurrent and of a more indolent course than seen in other FHLs or XLP), 
splenomegaly, colitis and periodic fevers (Pachlopnik Schmid et al. 2011; Yang et al. 2012; 
Speckmann et al. 2013; Aguilar and Latour 2015).  In contrast to XLP patients, lymphoma has not 
been reported in patients with XIAP deficiency.  Hypogammaglobulinaemia is also less common (67% 
vs 33%) (Pachlopnik Schmid et al. 2011) and has been described subsequent to EBV infection.  
Interestingly female carriers may also exhibit symptoms including erythema nodosum and 
inflammatory bowel disease (Dziadzio et al. 2015).  The outcome for XIAP patients receiving HSCT 
following myeloablative conditioning is poor with historical data reporting a survival of 14% (Marsh 
et al. 2013).  Mortality was due to transplant related toxicity in most cases highlighting the sensitivity 
of these patients to chemotherapy, likely related to the loss of XIAP’s anti-apoptotic function.  
Results are more favourable with RIC; survival increases to 55% overall, and 86% if patients are in 
remission from HLH at the time of transplant (Marsh et al. 2013).  Minimal intensity conditioning 
using anti-CD45 monoclonal antibodies has also been successfully employed (Worth et al. 2013). 
ITK deficiency 
Interleukin-2 inducible T cell kinase (ITK) is another recently described autosomal recessive PID 
associated with EBV-driven LPD, Hodgkin’s lymphoma and, unusually, non-Hodgkin’s lymphoma has 
also been reported (Huck et al. 2009; Serwas et al. 2014; Mansouri et al. 2012; Stepensky et al. 2011; 
Linka et al. 2012).  ITK is a member of the TEC kinase family (which includes BTK) and is required for 
normal development and signalling in lymphoid cells.  Progressive reduction in CD4+ T cells, naïve 
CD4+ T cells and NKT cell numbers is a common feature along with hypogammaglobulinaemia.  
Clinical features are primarily related to EBV associated lymphoproliferation but infections 
associated with T-cell deficiencies (Pneumocystis jiroveci, CMV, VZV and candida) have also been 
reported.  9 patients have been described to date, 8 presenting with LPD between the ages of 3 and 
13 years (Ghosh et al. 2014).  6 patients have died with 5 succumbing within 2 years of presentation 
despite treatment, demonstrating the devastating course of this condition.  Fever and 
lymphadenopathy were found in all patients with hepatosplenomegaly and significant lung 
involvement in 5/8 symptomatic individuals.  The presence of autoimmunity in 3 and HLH in 2 
suggests an underlying immune dysregulatory component to the disease but all patients so far have 
been EBV+ at diagnosis making it difficult to dissect out the role of EBV.  Despite high viral loads the 
serological findings are variable, again suggesting an element of dysregulated immune response.  ITK 
deficiency can be diagnosed through immunoblot to detect protein expression with confirmatory 
sequence analysis.  The response to chemotherapy protocols to treat malignancy is variable.  Some 
benefit has been shown for rituximab therapy and aciclovir but steroids do not appear to ameliorate 
the clinical features (Ghosh et al. 2014; Cipe et al. 2015).  Two patients have received HSCT (1 MSD, 1 
haploidentical donor) with one patient surviving (Ghosh et al. 2014).  The optimal management 
strategy for patients with ITK deficiency is yet to be determined but close monitoring is essential. 
CD27 deficiency 
CD27 deficiency is a diagnosis to consider in patients with severe EBV disease, 
hypogammaglobulinaemia and recurrent infection.  It is inherited in an autosomal recessive fashion.  
As an increasing number of cases are reported our understanding of the clinical spectrum of this 
disease is improving.  CD27 is a member of the TNF receptor family and a co-stimulatory molecule 
important for the development T, B and NK-cells, in particular memory B cells.  As CD27 is a widely 
used marker in the analysis of B and T cell subsets by flow cytometry, initial screening for this 
condition is both simple and reliable with all proven CD27 deficient patients having either absent 
CD27 expression (9/11 tested) or severely reduced expression (2/11)(Alkhairy et al. 2015).  Reduced 
numbers of NKT cells have been reported in severely affected individuals but impaired NK-cell 
function may be a more consistent immunological finding (Alkhairy et al. 2015).  Impaired T-cell 
dependent B-cell responses due to defective CD4+ T cell help lead to compromised cellular and 
humoral immunity, and patients may be misdiagnosed with CVID (Salzer et al. 2013; van Montfrans 
et al. 2012).  To date 17 patients have been described and it is apparent that the clinical phenotype 
is variable ranging from asymptomatic absence of memory B-cells and hypogammaglobulinaema, to 
EBV driven HLH and LPD, with no genotype-phenotype correlation (van Montfrans et al. 2012; Salzer 
et al. 2013; Alkhairy et al. 2015).  Median age at presentation of symptomatic patients was 6 years in 
this cohort (range 1-22 years) with a reported mortality of 29% (Alkhairy et al. 2015).  Many patients 
received immunoglobulin replacement therapy, rituximab and appropriate lymphoma treatment.  
Three patients underwent RIC mismatched unrelated cord blood transplant and are alive with the 
longest follow up of 4.5 years.  Close monitoring of asymptomatic patients is crucial to allow early 
intervention in EBV driven disease.  
XMEN (X-linked, magnesium defect, EBV, neoplasia) 
XMEN is a recently described serious PID caused by mutations in the MAGT1 gene, encoding the 
magnesium transporter 1 protein (Li et al. 2011; Li et al. 2014).  It is characterised by chronic EBV 
infection with high viral loads and increased susceptibility to lymphoma and LPD.  To date 8 patients 
have been described with an age at diagnosis of 3-58 years (Ravell, Chaigne-Delalande, and Lenardo 
2014; Dhalla et al. 2015).  They do not appear to develop HLH or other overt features of immune 
dysregulation unlike the other X-linked lymphoproliferative disorders.  A decreased CD4:CD8 ratio is 
a consistent finding, with abnormal TCR signalling but significant humoral defects have not been 
described (Li et al. 2014).  Due to abnormal magnesium flux in NK and T-cells, although viral specific 
cells are produced they fail to function sufficiently to control EBV infection.  Patients have been 
reported to develop other viral infections such as Molluscum, HSV and VZV alongside recurrent 
sinopulmonary infections (Ravell, Chaigne-Delalande, and Lenardo 2014).  Haematological 
malignancy is reported in all post-pubertal patients described, with many experiencing LPD earlier in 
life, and recurrent malignancy described in 2 patients. 
Two patients received HSCT at the ages of 23 and 45 years but both died in the early post-transplant 
period from transplant related complications (Li et al. 2014).  There is a suggestion from in vitro data 
and use in 2 patients that oral magnesium supplementation can increase NK-cell cytolytic activity 
and EBV control and, although highly experimental, it appears safe and well tolerated (Chaigne-
Delalande et al. 2013). 
STK4 Deficiency 
Serine threonine kinase 4 (STK4) (also known as MST1) deficiency is an autosomal recessively 
inherited combined immunodeficiency characterised by progressive CD4 lymphopenia.  STK4 is a 
ubiquitously expressed constituent of the HIPPO signalling pathway, which regulates cell 
proliferation, migration and apoptosis (Zhao, Tumaneng, and Guan 2011).  Specifically, in human 
immune cells STK4 plays a critical role in preventing lymphocyte apoptosis (Abdollahpour et al. 2012; 
Nehme et al. 2012), thymic egression (Tang et al. 2015) and leucocyte migration (Dang et al. 2016).   
13 patients with STK4 deficiency are reported in the published literature (Nehme et al. 2012; Halacli 
et al. 2015; Crequer et al. 2012; Abdollahpour et al. 2012; Dang et al. 2016).  Combining these 
patients with our experience of 3 unpublished cases (16 in total),  13 patients have been exposed to 
EBV, and 11 have developed chronic viraemia.  5 patients have developed EBV driven 
lymphoproliferation or malignancy at a median follow up of 11 years of age.  Additionally, these 
patients have recurrent invasive bacterial infections, severe cutaneous viral infections, 
mucocutaneous candidiasis and autoimmune cytopenias.  Immunologically they demonstrate a 
progressive CD4+ lymphopenia with impaired thymic output, increased susceptibility to apoptosis 
and a panhypergammaglobulinaemia suggestive of immune dysregulation (Abdollahpour et al. 2012; 
Nehme et al. 2012).  Vaccine and antibody responses are characteristically normal, including a 
normal serological response to EBV infection.  In some kindred, intermittent neutropenia and 
congenital cardiac defects have been described.  7 patients have been treated by HSCT.  4 patients 
died of a combination of infectious, toxicity related and GVHD complications, the remaining 3 
patients are alive and well, and apparently cured of their immunodeficiency (Nehme et al. 2012; 
Dang et al. 2016). 
CTP synthetase 1 (CTPS1) Deficiency 
CTPS1 deficiency has been recently described in 8 patients, as an autosomal recessive combined 
immunodeficiency, caused by a defect in lymphocyte proliferation following antigen receptor 
stimulation (Martin et al. 2014).  CTP synthesis contributes to the free cellular CTP pool, essential for 
efficient cell division.  CTPS1 activity is induced following TCR activation, and deficiency results in a T-
cell proliferative defect despite normal TCR activation signalling.  Clinically, these patients are 
susceptible to severe viral infections, and bacterial infection with capsulated bacteria, suggesting 
both a functional defect of T-cell cytotoxicity and T-independent B-cell immunity.  The clinical 
penetrance of immunodeficiency appears high, with the majority of patients presenting within the 
first 2 years of life.  All patients developed chronic EBV viraemia, with 4/8 patients developing severe 
IM and 3/8 developing CNS LPD.  6 patients received an HSCT and 4 remain alive and well, and free 
of symptoms. 
Coronin 1A Deficiency 
Coronin 1A deficiency was originally described as a thymic egress defect causing T- B+ NK+ severe 
combined immunodeficiency (SCID)(Shiow et al. 2008).  Like other immunodeficiencies caused by 
actin cytoskeletal defects, Coronin 1A deficiency impacts on a wide range of lymphocyte processes, 
including development, survival, TCR signalling, immune synapse formation and migration (Foger et 
al. 2006; Punwani et al. 2015; Mace and Orange 2014; Mugnier et al. 2008).  Impaired calcium flux 
and f-actin accumulation at the immune synapse result in increased T-cell apoptosis, compounding 
the CD4+ lymphopenia.  A total of 9 patients have been described with Coronin 1Adeficiency (Shiow 
et al. 2008; Moshous et al. 2013; Mace and Orange 2014; Stray-Pedersen et al. 2014; Punwani et al. 
2015; Yee et al. 2016), the majority with a typical SCID clinical presentation.  Patients have an 
immunophenotype of absent or low naïve T-cells, severely impaired T proliferative responses, 
normal levels of total immunoglobulins, and impaired (but not absent) vaccine responses.  Unlike 
other forms of SCID, Coronin 1A deficient patient have normal volume thymic tissue.  5/9 patients 
have developed EBV driven B cell lymphomas, and generally these have been at an earlier age than 
in other susceptible primary immunodeficiencies, with 4/5 patients developing EBV-driven LPD prior 
to 15 months of age.  2 patients died of their lymphomas prior to HSCT.  No patients have developed 
HLH or severe IM.  3 patients to date have been treated with HSCT.  1 is alive and well, but 2 died 
following HSCT (GVHD, relapsed diffuse large B cell lymphoma).  
Activated Phosphatidylinositide 3-Kinase delta syndrome (APDS) 
Gain of function mutations in the phosphatidylinositide 3-kinase delta (PI3Kδ) subunit p110δ cause a 
combined immunodeficiency of variable clinical severity, characterised by recurrent sino-pulmonary 
infections, increased susceptibility to viral infections, lymphoproliferation, progressive lung damage 
(bronchiectasis) and an autosomal dominance inheritance pattern (Angulo et al. 2013; Lucas et al. 
2014).  PI3Kδ is a lipid kinase which mediates the phosphorylation of PIP2 to generate PIP3, an 
important second messenger in the downstream signalling of T and B-cell antigen receptors, 
costimulatory receptors, cytokine receptors  and some Toll-like receptors (Okkenhaug 2013).  
Unregulated activity results in hyperactivation of the Akt-mTOR pathway, which in patient 
lymphocytes results in excessive terminal effector differentiation, increased activation induced cell 
death in T-cells, impaired cytokine production and impaired immunoglobulin class switching in B-
cells (Angulo et al. 2013; Lucas et al. 2014).  The immunophenotype of affected patients shows 
progressive lymphopenia, impaired T proliferative responses, impaired antibody responses to 
capsulated bacteria, increased circulating transitional B-cells and raised IgM levels.  Although neither 
haemophagocytic syndrome nor severe IM have been described in APDS, a high incidence of chronic 
EBV viraemia has been described (Kannan et al. 2015; Lucas et al. 2014).  Of 43 patients with APDS 
described in the literature, 9 (21%) have developed haematological malignancy or LPD, of which 3 
were EBV positive, and two were undefined (Crank et al. 2014; Angulo et al. 2013; Kannan et al. 
2015; Lucas et al. 2014; Kracker et al. 2014; Hartman et al. 2015).  Diffuse large B-cell lymphoma was 
described in 3 patients and Hodgkin’s Disease in a further 3 patients.  There is one published patient 
who has been successfully treated by HSCT and we have transplanted a second patient without 
complication (unpublished).  Inhibition of mTOR activity with Rapamycin has been used to 
successfully ameliorate the disease and has improved the immunophenotype in patients (Lucas et al. 
2014).  With the availability of selective PI3Kδ inhibitors, pharmacological blockade offers an 
attractive line of treatment for these patients. 
Radiosensitive SCID 
Defects of the non-homologous DNA end joining mechanism result in T- B- NK+ SCID, but clinical 
severity of defects in this pathway are heterogeneous, with several patients described with a 
hypomorphic phenotype.  Case reports for hypomorphic DNA ligase IV and Artemis gene mutations 
demonstrate susceptibility for EBV driven-LPD or diffuse large B-cell lymphoma, however HLH has 
not been seen (Woodbine, Gennery, and Jeggo 2014; Moshous et al. 2003; Toita et al. 2007; Enders 
et al. 2006).  Although numbers are small for each of these conditions, the incidence of EBV LPD 
seems to be between 20-50% of described patients. 
Ataxia Telangectasia (AT) 
AT is an autosomal recessively inherited syndrome characterised by progressive cerebellar ataxia, 
oculomotor dyspraxia, oculocutaneous telangiectasia, immunodeficiency and susceptibility to 
malignancy.  It is caused by mutations in the phosphatidylinositol 3-kinase family protein, ATM, 
which plays an integral role in DNA repair and cell cycle checkpoint control.  The immunodeficiency 
in AT is highly variable, but usually combined with low immunoglobulin levels, defective 
polysaccharide antibody responses and mild CD4+ lymphopenia (Chopra et al. 2014).  A recently 
published French registry study demonstrated a 19.1% incidence of lymphoma in patients with AT by 
20 years of age.  Approximately 1/3rd of these lymphomas were Hodgkins Diseases (all tested were 
EBV related) and 2/3rds were NHL (50% EBV positive) (Suarez et al. 2015).  HLH, SIM or chronic EBV 
viraemia has not been described in AT. 
CD16 deficiency 
Although only 3 patients have been described with homozygous mutation in the gene coding for 
CD16, two have developed EBV related severe complications (prolonged IM (de Vries et al. 1996), 
EBV-associated B-LPD (Grier et al. 2012)).  Patients have normal numbers of NK-cells, but impaired 
NK-cell cytotoxicity, and effected patients suffered from severe viral infections (particularly VZV and 
HPV in addition to EBV). 
Other Primary Immunodeficiencies with EBV susceptibility 
Although all diseases with impaired T cell function or number will struggle to respond appropriately 
to EBV infection, there are several other PIDs which, whilst not having the high penetrance of EBV-
associated disease of the above conditions, still frequently develop significant EBV pathology.  
Patients with Wiskott Aldrich Syndrome are at high risk of developing malignancy, particularly EBV-
driven B cell lymphoma.  Historical data suggests that without HSCT, over 10% of patients will 
develop malignancy with a median age of onset of 9.5 years (Sullivan et al. 1994).  There are also 
occasional cases of EBV-driven HLH in Wiskott Aldrich Syndrome (Pasic, Micic, and Kuzmanovic 2003; 
Bode et al. 2015).  Other monogenic disorders of NK-cells are also susceptible to severe viral 
infections.  Autosomal dominant mutations in the transcription factor GATA2 lead to the MonoMac 
syndrome (monocytopenia, B and NK-cell cytopenia, mycobacterial susceptibility, myelodysplasia).  
This progressive disorder can result in chronic EBV viraemia, and EBV associated malignancies 
(Spinner et al. 2014).  MCM4 deficiency is an autosomal recessive isolated NK-cell deficiency, caused 
by a proliferation and survival defect of terminally differentiated NK-cells (Gineau et al. 2012).  1/14 
patients described has developed EBV-associated B-cell LPD (Gineau et al. 2012; Hughes et al. 2012).  
Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of impaired lymphocyte apoptosis. 
There is a linear risk of developing lymphoma with age, and at 30 years 15% of patients have 
developed lymphoma with almost all being EBV positive (Price et al. 2014).  Two patients have also 
developed HLH (Bode et al. 2015).  WHIM (Warts, Hypogammaglobulinaemia, Immunodeficiency 
and Myelocathexis syndrome) is characterised by a susceptibility to severe papilloma virus and 
herpesvirus infections.  Two cases of EBV-associated LPD (fatal in one case) have been described 
(Chae, Ertle, and Tharp 2001; Imashuku et al. 2002). 
Conclusions and Future Directions 
Significant advances in recent years have increased our understanding of the host-virus interaction 
in EBV infection and better characterised the pathophysiology of severe and aberrant EBV infection.  
Treatment of these rare disorders, however, remains inconsistent and optimal therapeutic 
approaches are largely unknown.  Ongoing identification of new monogenic PIDs with specific EBV-
susceptibility, and further characterisation of the phenotype and natural history of already described 
conditions, will aid management strategies for these patients.  For patients without a discernible 
immunodeficiency, biomarkers to predict severe disease progression and those patients who would 
benefit from early HSCT are urgently needed.  With improving understanding of the pathophysiology 
of these conditions, identification of targeted biologic, cellular or small molecule therapies offers the 
best hope of managing these patients effectively and safely in the future.  
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Figure Legends 
Figure 1: The Epstein-Barr virus life cycle 
Following initial infection (typically through saliva) EBV establish a biphasic life cycle within the host, 
allowing non-productive genome maintenance in situations of immune surveillance, termed the 
latent cycle, and reactivating to the productive, infectious lytic cycle when in situations of primary 
infection or immune suppression.  EBV induces different stages of latency ( in B cells of different 
differentiation states, with progressively less viral protein and RNA production as B cells become 
more differentiated / less activated.  Individuals with chronic active EBV or other EBV genetic 
susceptibilities may be unable to mount an effective CTL or antibody response to lytically replicating 
EBV-positive cells, leading to high virus loads and constitutive immune activation.  Abbreviations: 
VCA – Viral caspid antigen, EA- Early antigens, EBER – EBV encoded small RNAs, EBNA – EBV nuclear 
antigen, LMP – Latent membrane protein, Tfh – T follicular helper cell. 
 
Figure 2: Clinical manifestations of EBV infection 
Although the vast majority of EBV infected individuals have an asymptomatic or self limiting primary 
infection (infectious mononucleosis), rare individuals develop more severe clinical syndrome as a 
consequence of an impaired ability to control lytic or latent EBV infection, or a the establishment of 
latent EBV infection in aberrant (non-B-cell) types.  These complications can be immune 
dysregulatory, leading to lymphproliferation and a local or systemic hyperinflammatory state, or 
they can be malignant.  Increasingly it appears that these pathologies are closely linked, with 
dysregulated inflammatory responses driving EBV-induced malignant proliferation.  As a consequent 
there is considerable overlap between many of the malignant and inflammatory EBV clinical 
syndromes.  The relationship between these main syndromes is shown in the figure.  Arrows 
represent clinical overlap or progression between individual clinical syndromes. 
 
Figure 3: Clinical investigation algorithm for chronic or pathological EBV infection 
We advocate an aggressive approach to the investigation of chronic EBV viraemia and pathological 
consequences of EBV infection.  Establishing the detailed immune state of the host, and the 
pathophysiology of infection, facilitates close monitoring of patients, assists targeting therapies, and 
helps identify which patients may benefit from early stem cell transplant.  The above algorithm 
provides an exhaustive list of investigation for patients presenting with EBV – associated 
haemophagocytic syndromes, CAEBV, chronic EBV viraemia, SIM, and EBV-driven malignancy.  It 
provides a framework for selecting investigations according to an individual patient’s clinical 
presentation and disease progress.  We do not propose that every patient should undergo every 
investigation listed above.  Management and assessment of these patients benefits from a 
multidisciplinary approach involving haematologists, immunologists, rheumatologist, Infectious 
diseases specialists, and specialist immunodeficiency and molecular genetics laboratory services.  
Abbreviations: TRECs – T-cell recombination excision circles, IgGAME – IgG, IgA, IgM, IgE, DHR - 
dihydrorhodamine assay, NBT - nitroblue tetrazolium assay, EM – electron microscope, FBC – full 
blood count, LDH – Lactose dehydrogenase, sCD25 – soluble CD25, PID – Primary Immunodeficiency 
, fHLH – familial HLH, WES – whole exone sequencing, WGS – whole genome sequencing, ANA – 
antinuclear antigen autoantibody, dsDNA – double stranded DNA autoantibody, ENA – Extractable 
nuclear antigen autoantibodies, Urinary alb:creat – urinary albumin : creatinine ratio, CMV – 
cytomegalovirus, HSV – Herpes simplex virus 1 and 2, VZV – varicella zoster virus, HHV6/7 – Human 
herpes virus 6 and 7, HIv – human immunodeficiency virus, BM – bone marrow, VCA – Viral caspid 
antigen, EA- Early antigens, EBER – EBV encoded small RNAs, EBNA – EBV nuclear antigen 
